Navigation Links
Internationally known neuroblastoma expert reviews progress versus challenging childhood cancer
Date:6/14/2010

Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledgemuch of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia. Maris directs a laboratory at CHOP in collaboration with the multicenter Children's Oncology Group (COG) using tissue samples from 5,000 patientsthe world's largest sample collection for neuroblastoma.

A cancer of the sympathetic nervous system, neuroblastoma most commonly occurs as a solid tumor arising from the adrenal gland in the abdomen. Neuroblastoma remains one of the most puzzling of childhood cancersranging from cases of widespread but benign tumors in infants that spontaneously and completely disappear, to high-risk subtypes in older children that are relentlessly aggressive.

Maris is the chief of Oncology at Children's Hospital and director of the Hospital's Center for Childhood Cancer Research. Just three years ago, he wrote a review article on neuroblastoma for The Lancet. Since that time, a stream of discoveries from his lab has explored the genetic landscape of neuroblastoma. In 2008, Maris led the team that identified common DNA variations on chromosome 6, the first time researchers found the cancer's genetic origin. Later that year, Yael Mosse, M.D., collaborating at CHOP with Maris, reported that mutations in the ALK gene were the main cause of inherited neuroblastoma, and also played a role in many cases of non-inherited neuroblastoma. In 2009, Maris published two more gene studies, identifying common variants in the gene BARD1 and copy number variants on chromosome 1 that raised the risk of neuroblastoma. The latter study was the first ever to find a specific copy number variant that predisposes to a human cancer.

The ultimate goal of basic research at CHOP is to translate findings into more effective treatments for children. To that end, the Cancer Center at CHOP is currently leading a clinical trial of an ALK inhibitor for children who have relapsed after neuroblastoma treatments. In his review, Maris describes other innovative therapies, such as a national immunotherapy trial by the COG, using monoclonal antibodies and cytokines to selectively target neuroblastoma cells. Another experimental treatment, developed at CHOP and other centers, uses MIBG, a radioactive isotope that zeroes in on neuroblastoma cells. Maris also cites federally sponsored collaborative programs designed to identify new drugs that will interrupt the key cell signaling pathways that drive neuroblastoma.


'/>"/>

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-426-6063
Children's Hospital of Philadelphia
Source:Eurekalert  

Related medicine news :

1. Sanford Heart Hospital Physicians Again Recognized Internationally for Innovative Techniques
2. Northern California Cancer Centers Findings on Breast Cancer and Secondhand Smoke Released Internationally by the American Association for Cancer Research
3. Reno Children With Disabilities Profit From a Little Known but Internationally Recognized Non-Profit Organization as it Quietly Crosses the $200,000.00 Mark in Service Investment Into the Reno Area
4. American Red Cross Responds Internationally and at Home to Chile Quake
5. Dr. Mahaveer Mehta, A Well Known Dermatologist from Dubai, Receives Prestigious 'Hind Rattan Award'
6. Major Imaging Initiative to Shed Light on Little Known Brain Disease
7. Physicians Coalition Asks Federal Court to Block Obama Healthcare: Doctors Claim Bill Would End Practice of Medicine as We Have Known It, Assert Presidents Actions Are Unconstitutional
8. Yoga reduces cytokine levels known to promote inflammation
9. Penn researchers find genetic link to leukemias with an unknown origin
10. Nationally Known Interventional Neuroradiologist John Pile-Spellman, M.D., Joins Neurological Surgery, P.C.
11. Chiropractic Traffic CEO Matt Prados Releases the Easiest and Fastest Free Chiropractic Marketing Method Known to Man
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Internationally known neuroblastoma expert reviews progress versus challenging childhood cancer
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Over 40 ... convened in the state capitol for the annual “Hike to Harrisburg” advocacy day. ... and The Winter Group, PATS lobby Group. The goal for the day was ...
(Date:5/4/2016)... ... ... , a leading provider of barcode and RFID labels has acquired ... to continue to grow its label business, customer base and market share. , Netc ... print and label tape media on site and on an as needed basis. Many of ...
(Date:5/3/2016)... ... May 03, 2016 , ... ProIntro Glitch is a set of ... Film Studios’ titles allow users to add a terrifying opener to any video or ... lines and accents. To add greater contrast, all the user has to do is ...
(Date:5/3/2016)... ... May 03, 2016 , ... Sue Desmond-Hellmann, chief executive officer ... to stretch the limits of human possibility in her keynote address at Georgia State ... Georgia Dome. , Drawing on her rich experience as a scientist, physician and executive, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Calvary Hospital recently hosted a reception to ... a 10-bed unit located at Mary, Manning Walsh Home (MMW) in Manhattan. , ... DGH for half an hour, once a week. The music brings a lot of ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... YORK , May 2, 2016 Kalorama ... EMR (Electronic Medical Records) market in a recent white ... sales, vendor switches, Increased physician usage, a growing market are ... were noted in Kalorama,s report EMR 2016: ... report marks Kalorama,s seventh complete study of the EMR ...
(Date:5/2/2016)... NEW YORK , May 2, 2016 /PRNewswire/ ... Series B financing of Graybug Vision, Inc. Graybug ... to developing therapies that may transform care for ... and glaucoma.  Graybug Vision,s technology was first developed ... out into a startup venture. ...
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
Breaking Medicine Technology: